<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587064</url>
  </required_header>
  <id_info>
    <org_study_id>APDIC</org_study_id>
    <nct_id>NCT03587064</nct_id>
  </id_info>
  <brief_title>Comparison of CRT-D and CRT-DX Systems (CRT-NEXT)</brief_title>
  <acronym>CRT-NEXT</acronym>
  <official_title>Non-inferiority Randomized Clinical Investigation of CRT-DX Versus CRT-D Systems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associazione Portatori Dispositivi Impiantabili Cardiaci</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Associazione Portatori Dispositivi Impiantabili Cardiaci</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal objective is to test non-inferiority of the CRT-DX system as compared to a
      conventional CRT-D system, in terms of the combined endpoint of mortality, hospitalizations
      due cardiovascular causes, any complication leading to loss of lead functionality, in the
      subset of patients without evidence of sinus dysfunction on optimal therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Resting heart rate is strongly associated with incident worsening Heart Failure (HF) and
      mortality. Current devices for cardiac resynchronization (CRT-D) normally provide
      atrio-ventricular (AV) sequential pacing modes during resynchronization, but the best pacing
      programming strategy is not clear.

      On the one hand a basic rate of 50 to 70 bpm (optionally with some rate-responsive function)
      could be considered for therapy up-titration, specifically betablockers; on the other hand,
      increasing pacing rates may partially reduce benefits from resynchronization, reducing
      filling time and contractility reservoir.

      The Pegasus investigation is the only large randomized investigation comparing DDD with 70
      bpm basic rate to DDD(R) @40 bpm. Results showed no difference in investigation endpoints,
      including mortality and HF-hospitalization.

      These results may support the use of a device implementing both a CRT function and a right
      ventricular single-lead with and an atrial sensing dipole (CRT-DX system). This system can
      track ventricular pacing and resynchronization following atrial sensing, even if it cannot
      provide atrial pacing support. It should be assessed whether such limitation is
      counterbalanced by the advantages related to the reduced number of necessary leads, with
      simplified implantation and less complications.

      The objective of the investigation is to assess whether atrial pacing support is really
      necessary in the subset of patients with indication to CRT-D and no evidence of sinus
      dysfunction on optimal therapy. The investigation will test the hypothesis that a CRT-DX
      system is not inferior to a conventional CRT-D system in this class of subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined endpoint of Mortality, hospitalization due to cardiac causes and lead-related complications</measure>
    <time_frame>1 year</time_frame>
    <description>It includes number of patients who experienced death, hospitalization due to cardiac causes, or any lead-related complication leading to loss of functionality (including lead dislodgement, conduction or insulation failure, loss of sensing or capture that couldn't resolved by reprogramming)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of implant revisions</measure>
    <time_frame>1 year</time_frame>
    <description>Rate of implant revisions to add, replace, reposition, and remove an atrial pacing lead.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of inappropriate therapy of the device</measure>
    <time_frame>1 year</time_frame>
    <description>Inappropriate detections and interventions of high rate ventricular episodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial pacing percentage</measure>
    <time_frame>1 year</time_frame>
    <description>In the conventional CRT-D group, atrial pacing percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise test</measure>
    <time_frame>1 year</time_frame>
    <description>Six minute walking test distance at one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device detected AT</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of atrial tachyarrhythmias (AT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of appropriate Ventricular therapy</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of Ventricular Arrhythmias (VA) requiring therapy delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of events due to short-long-short sequence</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of both VA and AT due to bradycardia or short-long-short sequence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant failure</measure>
    <time_frame>1 year</time_frame>
    <description>Impossibility to implant any component (leads and device) of the initially planned system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure times</measure>
    <time_frame>1 year</time_frame>
    <description>Skin-to-skin and fluoroscopy time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial sensing amplitude measured by device</measure>
    <time_frame>1 year</time_frame>
    <description>Atrial sensing amplitude measured by devices in both investigation arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Far field oversensing incidence</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of far field oversensing episodes in both investigation arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">640</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiac Resynchronization Therapy</condition>
  <arm_group>
    <arm_group_label>3-lead CRT implantation (CRT-D)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the 3-lead CRT implantation (CRT-D) group, conventional 3-lead CRT defibrillator system implantation will be performed. The CRT-D system is composed by three leads, one in atrium and two in both ventricles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-lead CRT implantation (CRT-DX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the 2-lead CRT implantation (CRT-DX) group, 2-lead CRT defibrillator system implantation will be performed. The CRT-DX system is composed by two ventricular leads, the right one is provided with a dipole for atrial sensing</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional 3-lead CRT defibrillator system implantation</intervention_name>
    <description>Conventional 3-lead(1 atrial and 2 ventricular leads) system implantation</description>
    <arm_group_label>3-lead CRT implantation (CRT-D)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>2-lead CRT defibrillator system implantation</intervention_name>
    <description>2-lead (2 ventricular leads with dipole for atrial sensing) DX system implantation</description>
    <arm_group_label>2-lead CRT implantation (CRT-DX)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients ≥ 18 years old

          2. Patients willing to participate in the investigation and signing the Patient Informed
             Consent (PIC) Form;

          3. Indication to CRT-D implant according to current ESC Guidelines on cardiac pacing and
             cardiac resynchronization therapy

          4. Sinus rhythm at time of implant;

          5. Optimized medical therapy according to current ESC Guidelines

          6. Rest heart rate (HR) &gt;45 bpm at baseline ECG, with betablocker therapy at optimal
             medical dosage; or, if rest HR&lt;45 bpm: maximum heart rate at the 6- minute walking
             test &gt;85 bpm.

        Exclusion Criteria:

          1. Any indication to atrial pacing according to current guidelines;

          2. Both: resting heart rate &lt;45 bpm at baseline ECG, with betablocker therapy at optimal
             medical dosage and maximum heart rate at the 6-minute walking test &lt;85 bpm;

          3. NYHA Class IV;

          4. Permanent Atrial Fibrillation

          5. Replacement of/upgrading from previously implanted pacing system;

          6. Dialysis patients;

          7. Pregnant or breast-feeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mauro Biffi, MD</last_name>
    <phone>0516363434</phone>
    <email>mbiffi64@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ASST Rhodense</name>
      <address>
        <city>Rho</city>
        <state>Milano</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Luca Botto, MD</last_name>
      <email>gluca.botto@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Ospedali Riuniti Ancona</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Capucci, MD</last_name>
      <email>a.capucci@univpm.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO Moscati</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felice Nappi, MD</last_name>
      <email>felice.nappi.81@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Biffi, MD</last_name>
      <email>mbiffi64@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Giovanni Paolo II</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matteo Santamaria, MD</last_name>
      <email>matteosantamaria@yahoo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO S. Sebastiano</name>
      <address>
        <city>Caserta</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miguel Viscusi, MD</last_name>
      <email>miguel.viscusi@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele - Presidio Ferrarotto</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeria Calvi, MD</last_name>
      <email>valcalvi@unict.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giampiero Maglia, MD</last_name>
      <email>pmaglia@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ennio Pisanò, MD</last_name>
      <email>enniopisano@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Mater Salutis di Legnago</name>
      <address>
        <city>Legnago</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Zanotto, MD</last_name>
      <email>gabzanot@tin.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Carlo Poma</name>
      <address>
        <city>Mantova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrizia Pepi, MD</last_name>
      <email>patrizia.pepi@asst-mantova.it</email>
    </contact>
    <investigator>
      <last_name>Albino Reggiani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Rovaris, MD</last_name>
      <email>gi.rovaris@tin.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO dei Colli - PO Monaldi</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio D'Onofrio, MD</last_name>
      <email>donofrioant1@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Rapacciuolo, MD</last_name>
      <email>antonio.rapacciuolo@unina.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Toscana Gabriele Monasterio</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcello Piacenti, MD</last_name>
      <email>marcello.piacenti@ftgm.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Domenico Sergi</last_name>
      <email>domenico.sergi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Francesco Romeo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Trieste</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massimo Zecchin, MD</last_name>
      <email>massimo.zecchin@alice.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi, Cardiologia 1</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrizio Caravati, MD</last_name>
      <email>fabrizio.caravati@alice.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>January 10, 2019</last_update_submitted>
  <last_update_submitted_qc>January 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRT-D</keyword>
  <keyword>CRT-DX</keyword>
  <keyword>Atrial pacing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

